Marketing of Proteins and Peptide Pharmaceuticals

Marketing of Peptide, Proteins, Author: Sasan Nasoohi Function : Sales Manager Schering Plough Date : Nov 08 Presented to Ph.D. students of Faculty of Pharmacy of Tehran University

Proteins, eventually !! ,[object Object]

Proteins: disease and remedy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Proteins are drugs ! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Peptide Pros and Cons ,[object Object],[object Object],[object Object],[object Object]

Origin of peptide products ,[object Object],[object Object],[object Object],[object Object],[object Object]

Peptide Pharmaceuticals ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Protein Therapeutics ,[object Object],[object Object],[object Object]

Major Brands > $ 1 Mln ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Iran Sales 4 month ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Cost-effectiveness ,[object Object],[object Object],[object Object],[object Object],[object Object]

Production Costs ,[object Object],[object Object],[object Object],[object Object]

What is PharmacoEconomics (PE)? Inputs Costs Health Care Outcomes

Pharmacoeconomics (PE) ,[object Object],[object Object],[object Object]

Costs ,[object Object],[object Object],[object Object]

Costs ,[object Object],[object Object],[object Object],Advantages: High Activity, High Specifity, Little unspecific binding to molecular structure other that desired target, Minimization of drug-drug interactions, Less accumulation in tissues, Lower toxicity, Often very potent, Biological diversity

Costs can be described in many ways ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Outcomes ,[object Object],[object Object],[object Object]

Most Active Developments ,[object Object],[object Object]

The top 10 biotechnology companies

Challenges ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Challenges ,[object Object],[object Object],[object Object],[object Object]

Current FDA Policy for approval of rDNA-derived Products ,[object Object],[object Object],[object Object],[object Object]

Determining the Degree of Similarity of Proteins ,[object Object],[object Object],[object Object],[object Object]

Product Comparability Testing ,[object Object],[object Object],[object Object],[object Object]

Pharmaceutical Equivalence (PE) ,[object Object],[object Object],[object Object],[object Object]

The ICH S6 Document ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Toxicology Testing of Biotech-Derived Agents: ICH-S6 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Feature of Benefit? ,[object Object],[object Object]

Marketing of Proteins and Peptide Pharmaceuticals

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (20)

Ähnlich wie Marketing of Proteins and Peptide Pharmaceuticals

Ähnlich wie Marketing of Proteins and Peptide Pharmaceuticals (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Marketing of Proteins and Peptide Pharmaceuticals